Effects of a synthetic estrogen upon steroid bioconversion in vitro in testes of patients with prostatic cancer.
D006907:17-alpha-Hydroxypregnenolone / Q000378:metabolism; D000284:Administration, Oral; D000368:Aged; D000735:Androstenedione / Q000378:metabolism; D004794:Enzyme Repression; D006589:Hexestrol / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006908:Hydroxyprogesterones / Q000378:metabolism; D006913:Hydroxysteroid Dehydrogenases / Q000378:metabolism; D066298:In Vitro Techniques; D007535:Isomerases / Q000378:metabolism; D008190:Lyases / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000378:metabolism; D009249:NADP / Q000494:pharmacology; D011374:Progesterone / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D013091:Spermatogenesis / Q000187:drug effects; D013256:Steroids / Q000378:metabolism*; D013737:Testis / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology / Q000601:surgery; D013739:Testosterone / Q000378:metabolism
D006908:Hydroxyprogesterones; D013256:Steroids; D006589:Hexestrol; D006907:17-alpha-Hydroxypregnenolone; D013739:Testosterone; D000735:Androstenedione; D011374:Progesterone; D009249:NADP; D006899:Mixed Function Oxygenases; D006913:Hydroxysteroid Dehydrogenases; D008190:Lyases; D007535:Isomerases